Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vanguard Information Technology Index Fund ETF trades at $115.5. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Information Technology Index Fund ETF pays none, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VGT | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $125.77 |
52-Week Low | $545.46 | $83.59 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VGT trades at $113.23, showing minimal daily movement with a 0.11% gain. Technical indicators signal bearish momentum with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions near support at $113. Recent news highlights strong long-term performance with 25% average annual returns over 10 years, while current market focus centers on semiconductor sector volatility and AI-driven growth prospects.
The ETF's outlook remains positive for long-term investors despite near-term technical weakness, with technology sector dominance and AI exposure providing growth catalysts. Key risks include semiconductor concentration, valuation concerns after recent run-ups, and broader market volatility. Wall Street maintains constructive views on tech sector leadership through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
